pRCC, on the other hand, frequently bears mutations in the hepatocyte growth factor receptor (MET proto-oncogene), SETD2 and Moesin-Ezrin-Radixin Like Tumor Suppressor (NF2), while chRCC tumors are characterized by TP53 and Phosphatase and tensin homolog (PTEN) mutations [14]. Here, MET is linked to chromophobe renal cell carcinoma.